Most people who wanted tirzepatide compounding pharmacy access a year ago had options. Telehealth platforms were selling it. Some doctors were prescribing it through 503A pharmacies. You could get a vial for a fraction of the brand-name cost and mix it yourself at home.
That world is mostly gone now.
If you are trying to figure out what actually happened, what is still legal, and where to get tirzepatide in 2026, here is the straight story.
What Is Tirzepatide Compounding, Really
Tirzepatide is the active molecule in Eli Lilly's Mounjaro and Zepbound. It is a dual GIP/GLP-1 receptor agonist that works on two hunger pathways at once, which is why it tends to produce stronger weight loss results than GLP-1 agonists alone.
Compounding is when a pharmacy mixes a drug into a different form or dose than what is commercially available. For tirzepatide, this usually meant:
- Reconstituting lyophilized (freeze-dried) tirzepatide powder into injectable solutions
- Creating alternative dose strengths not available in brand formulations
- Sometimes adding dilution agents to make smaller doses easier to measure
Compounding exists because some patients have legitimate needs that commercial drugs cannot meet. A person who needs a very small dose, or who has an allergy to an inactive ingredient in the brand drug, genuinely benefits from compounding.
But the tirzepatide compounding boom was not mostly driven by those patients. It was driven by people who could not afford the list price of Mounjaro or Zepbound, which ran around $1,023 per month without insurance.
Cheaper compounded tirzepatide was the workaround. And Eli Lilly noticed.
The FDA Timeline: How Compounded Tirzepatide Got Shut Down
The FDA's crackdown on tirzepatide compounding followed a predictable pattern, once you understand how the shortage list works.
October 2, 2024: Tirzepatide Gets Removed From the FDA Shortage List
The FDA maintains a register of drugs in shortage. When a drug is on that list, compounding pharmacies can legally produce copies of it under Section 503A of the Federal Food, Drug, and Cosmetic Act, because the drug is considered "essentially a copy" of an unavailable product.
When tirzepatide was removed from the shortage list, that legal justification evaporated overnight. Eli Lilly had successfully argued that supply was sufficient to meet demand.
November through December 2024: The Grace Period
After removal from the shortage list, compounding pharmacies entered a grace period where existing stocks could still be sold. Many did a brisk business clearing inventory during this window.
March 2025: Enforcement Discretion Ends for 503A Pharmacies
The FDA formally ended enforcement discretion for 503A pharmacies (the traditional corner-store compounding pharmacies). These are the ones that need a prescription for each patient and cannot produce drugs in bulk. They were no longer allowed to make tirzepatide.
Eli Lilly's Legal Offensive
Lilly did not stop at the FDA. The company filed trademark infringement lawsuits against several telehealth platforms and peptide vendors that were selling products labeled as tirzepatide. These cases were not all about safety. They were about market protection. Lilly holds the patents on the tirzepatide molecule, and those patents do not expire until 2036.
503A vs 503B Pharmacies: Does the Difference Matter Anymore
There are two types of compounding facilities, and the difference matters in 2026, though not necessarily in the way people expect.
503A Pharmacies are traditional compounding pharmacies that compound for individual patients with valid prescriptions. They are regulated by state boards of pharmacy and must follow USP <795> and <797> standards for non-sterile and sterile compounding respectively.
As of March 2025, these pharmacies can no longer produce tirzepatide. The FDA has been clear on this.
503B Outsourcing Facilities are different. They compound for healthcare facilities rather than individual patients, are inspected by the FDA rather than state boards, and do not require patient-specific prescriptions. They can produce larger batches.
503B facilities had more flexibility after the shortage list removal, but they are not immune. Several have faced FDA scrutiny and import alerts. The legal ground under them is shaky, and several major 503B tirzepatide producers have stopped advertising publicly.
The practical result: both pathways are effectively closed for most people who were using them.
The Telehealth Fallout
This is where it gets messy for consumers.
Platforms like Noom, Ro, and other telehealth companies had built significant businesses around prescribing compounded GLP-1 medications, including tirzepatide. After the FDA crackdown, most of these platforms quietly discontinued their compounded tirzepatide programs.
Some pivoted to semaglutide. Some pivoted to oral formulations. Some just shut down the relevant product lines entirely.
The people left holding the bag were the patients who had built their protocols around these platforms, had refills in progress, or had been told by their prescribers that compounded was just as good as brand.
Was it? That depends on the specific pharmacy, the quality assurance, and the formulation. But the legal pathway that allowed it is gone.
What Is Still Available in 2026
The crackdown did not eliminate tirzepatide. It changed where and how people get it.
Brand-name Mounjaro and Zepbound remain available by prescription. If you have insurance coverage or qualify for Eli Lilly's savings card (which can bring the cost to $25/month for eligible patients), this is the cleanest route. Without coverage, you are looking at roughly $1,023 per month.
Research-grade tirzepatide is available from several peptide suppliers that operate under the research-use exemption. These products are labeled not for human consumption, are sold as raw active pharmaceutical ingredients (API), and are intended for laboratory research or licensed compounding.
This is the category companies like Ascension Peptides fall into. They sell tirzepatide as T-10 (10mg vials) and T-30 (30mg vials). No prescription is required for purchase. Third-party certificates of analysis (COAs) are available for these products.
Is it the same molecule? Yes. Is it the same as getting a prescription from a doctor and using a pharmacy? No. The quality assurance pathway is different. Brand drugs go through FDA approval processes with batch testing that research suppliers do not replicate.
For people who understand the difference and are comfortable with the research-use framework, this is where most of the market has moved.
You can explore current research-grade tirzepatide options at Ascension Peptides, where T-30 vials run around $125 with COA documentation.
How to Reconstitute Research-Grade Tirzepatide
If you buy research-grade tirzepatide, it will arrive as a lyophilized powder. You need to reconstitute it before use.
The standard practice is:
- Sanitize the rubber stopper on the vial with an alcohol swab
- Use bacteriostatic water for injection as your reconstitution solvent
- Draw the appropriate amount of bacteriostatic water with a sterile syringe
- Inject it slowly into the vial, aiming at the side wall rather than directly into the powder cake
- Gently swirl until fully dissolved. Do not shake vigorously
- Store the reconstituted solution in the refrigerator
Reconstitution volume determines concentration. Common approaches:
- 1mL of bacteriostatic water into a 10mg vial = 10mg/mL solution
- 2mL of bacteriostatic water into a 10mg vial = 5mg/mL solution
Your target dose in micrograms or milligrams tells you how much to draw. A 150-microgram dose from a 10mg/mL solution would be 0.015mL or 15 microliters. Most people use an insulin syringe with 100-unit markings for this.
Reconstitution guides are specific to each supplier and batch. Always read the documentation that comes with your specific product.
Tirzepatide Dose Escalation: What a Standard Protocol Looks Like
Tirzepatide is started at a low dose and escalated every four weeks based on tolerability and response. The standard titration schedule from clinical trials looked like this:
- Weeks 1 through 4: 2.5mg once weekly (starting dose)
- Weeks 5 through 8: 5mg once weekly
- Weeks 9 through 12: 7.5mg once weekly
- Weeks 13 through 16: 10mg once weekly
- Weeks 17 through 20: 12.5mg once weekly
- Week 21 onward: 15mg once weekly (maximum dose)
Many users never reach the 15mg dose. They stay at 10mg or 12.5mg if that is where they see results they are happy with. Escalating to higher doses does not always produce meaningfully better outcomes, and higher doses come with higher rates of gastrointestinal side effects.
The most common side effects across all doses are nausea, diarrhea, constipation, and reduced appetite. These tend to be most pronounced during dose escalation and can be significant enough that some people discontinue treatment.
What About Compounded Semaglutide
Semaglutide (the active molecule in Ozempic and Wegovy) is also on the FDA shortage list, but its situation is different. Novo Nordisk has not successfully removed semaglutide from the shortage list the way Lilly did with tirzepatide. The shortage for semaglutide has been more persistent, and Novo's attempts to get it removed have faced more resistance.
As of early 2026, compounded semaglutide was still more accessible than compounded tirzepatide. Pharmacies that have stopped producing tirzepatide have in some cases shifted to producing compounded semaglutide instead.
If your primary goal is access rather than specifically tirzepatide, compounded semaglutide is worth looking into as a more available alternative.
How to Choose a Peptide Vendor
If you are buying research-grade tirzepatide, vendor quality varies enormously. Here is what to look for:
Third-party COAs (Certificates of Analysis)
Any reputable supplier can provide a COA from an independent laboratory confirming the purity and identity of their product. If a vendor cannot produce this, do not buy from them. If the COA is more than six months old, ask for a new batch-specific one.
Purity thresholds
Aim for 99%+ purity on the COA. Lower purity means more impurities, which is not what you want in an injectable.
Batch-specific testing
Suppliers that test every batch, not just once per production run, are more reliable. Ask whether the COA is batch-specific or just representative of older production.
Storage and handling
Tirzepatide is temperature-sensitive in its reconstituted form. Vials that have been shipped without cold-chain handling can degrade. Look for suppliers that use adequate packaging, even for room-temperature shipments of lyophilized powder.
Transparency about source
Some suppliers are vague about where their API comes from. Reputable suppliers will at least tell you which manufacturer they source from, even if they protect their supply chain details.
Safety Considerations
This article is for informational purposes. Here is what you need to know before making any decisions:
Tirzepatide is an investigational new drug when used outside of its FDA-approved indications. Using it without a prescription means you are operating outside the conventional medical system. That has implications:
- You do not have a prescriber monitoring your bloodwork, side effects, or metabolic response
- Adverse events you experience will not be caught by a healthcare provider
- There are no guarantees about formulation quality outside of FDA-regulated channels
People with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use GLP-1 agonists including tirzepatide. This is a contraindication in the branded drug labeling.
If you have diabetes, are pregnant or breastfeeding, or have any significant cardiovascular or gastrointestinal conditions, talk to a physician before using tirzepatide in any form.
The research-use exemption is real, but it is not a substitute for medical supervision.
Frequently Asked Questions
Can I still get compounded tirzepatide from a pharmacy?
In the United States, traditional 503A compounding pharmacies can no longer legally produce tirzepatide following its removal from the FDA shortage list. Some 503B outsourcing facilities may still produce it under their own legal framework, but access is limited and the legal status of those operations is not entirely settled.
What is the difference between research-grade and compounded tirzepatide?
Compounded tirzepatide is prepared by a pharmacy for a specific patient or facility, typically following a prescription. Research-grade tirzepatide is sold as an API for laboratory research purposes. Research-grade suppliers are not pharmacies and do not provide medical supervision.
How much does research-grade tirzepatide cost?
Ascension Peptides sells T-10 (10mg) for approximately $80 and T-30 (30mg) for approximately $125. These are vial prices and do not include bacteriostatic water, syringes, or other supplies you will need.
Do I need a prescription for research-grade tirzepatide?
No. Research-grade suppliers sell to laboratories and researchers. No prescription is required.
Is tirzepatide safe for everyone?
No. People with a history of MTC, MEN 2, or hypersensitivity to the drug should not use it. Common side effects include nausea, diarrhea, constipation, and injection site reactions. Rare but serious side effects have been reported in clinical trials. Medical supervision is recommended.
Can I use tirzepatide for weight loss without a doctor?
Technically yes, through research-use channels. But it means operating without medical oversight, which carries real risks. A telemedicine consultation or a GP familiar with peptide therapy is a better first step than self-prescribing.
Shop T-30 (Tirzepatide 30mg) at Ascension Peptides — $125/vial, COA available, no prescription required for research use. Browse all peptide options at Ascension Peptides.
Buy T-30 here: https://ascensionpeptides.com/ref/mihaita/?campaign=middle
This article is for informational purposes only. Tirzepatide is not approved for weight loss in all jurisdictions. Always consult a qualified healthcare provider before starting any new medication or supplement regimen.
